Magi Astrology--Financial Astrology

FINANCIAL ASTROLOGY

First Trade Date for Biogen, Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Biogen, Inc.	1983-03-22

Company Name	Symbol
Biogen, Inc.	BGEN
History and Business of Company (this information may include date of incorporation)
Biogen, Inc. (BGEN) is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the company's revenues are generated from international sales of AVONEX (Interferon beta 1-a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licenses of a number of products. Such products include certain forms of alpha interferon, hepatitis B vaccines and hepatitis B diagnostic test kits, among others. BGEN continues to have an active development program related to AVONEX, and is conducting several important clinical trials of the product. In 2000, BGEN announced the results of its CHAMPS trial, begun in 1996, to study the effect of AVONEX in delaying the development of clinically definite multiple sclerosis in patients who had experienced an isolated, well-defined neurologic event consistent with MS. The study showed a highly statistically significant beneficial effect of AVONEX on delaying the development of clinically definite multiple sclerosis as compared to the placebo. BGEN was conducting several other clinical studies of AVONEX. These include an open-label follow-up study initiated in 1995 to obtain long-term safety and antigenicity data and an open label follow-up study initiated in 2000 to study the long-term effect of AVONEX on patients who participated in the CHAMPS study. BGEN maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. The company's research is focused on biological systems and processes where its scientific expertise in molecular biology, cell biology, immunology and protein chemistry can lead to a greater understanding of disease processes and, as a result, to the creation of new pharmaceuticals. Research strategy is to direct its efforts toward finding therapeutics in four major research focus areas: fibrosis, oncology, immunomodulation, and neurodegeneration. Less specifically, the company's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. Total revenues in 2000 were $926.5 million, as compared to $794.4 million in 1999, an increase of approximately 17%. Revenues from sales of AVONEX in 2000 were approximately $761.1 million or approximately 82% of total revenues. Royalty revenues in 2000 were about $165.4 million. Product sales in 2000 were $761.1 million as compared to $620.6 million in 1999. INCORPORATED in Massachusetts June 29, 1988, and on Sept. 30, 1988, merged, share-for-share with predecessor, a Delaware concern of the same name. Predecessor was organized June 30, 1988, to succeed a Netherlands Antilles concern organized May 10, 1979 as Biogen N.V., successor to a Luxembourg concern founded in 1978. OFFICE- 14 Cambridge Center, Cambridge, MA 02142 (Tel.: 617-679- 2000). Fax - 617-679-2617. WEBSITE-http://www.biogen.com.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.